Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Overview of attention for article published in New England Journal of Medicine, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 51 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 132 X users
patent: 1 patent

facebook: 2 Facebook pages
reddit: 4 Redditors
guideline: 8 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 626 Mendeley

So far, Altmetric has seen 12 posts from 2 blogs.

Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer

Physician's Weekly, 06 Dec 2024

1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or…

Pembrolizumab with chemoradiotherapy improves survival in locally advanced cervical cancer

Physician's Weekly, 30 Oct 2024

1. 36-month overall survival was significantly greater in the pembrolizumab-chemoradiotherapy group compared to placebo-chemoradi…

Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer

Physician's Weekly, 01 May 2024

1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-c…

#VisualAbstract: Atezolizumab in addition to bevacizumab and platinum-based chemotherapy improves survival in metastatic cervical cancer

Physician's Weekly, 09 Feb 2024

1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 8 additional blog posts.